Voniza™
Vonoprazan
Potassium Competitive Acid Blockers (PCAB) (Antiulcerant)
Indication:
• Gastric ulcer (GU)
• Duodenal ulcer (DU)
• Reflux esophagitis (RE) and (erosive esophagitis EE)
• Maintenance treatment of reflux esophagitis (erosive esophagitis) in patients with repeat recurrence and relapse of the condition
• Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration
• Adjunct to Helicobacter pylori eradication associated with: Gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early stage cancer, or Helicobacter pylori gastritis
Dosage & Administration:
Indication | Dose | Frequency |
Gastric ulcer | 20 mg | Once daily for 8 weeks |
Duodenal ulcer | 20 mg | Once daily for 6 weeks |
Reflux esophagitis (erosive esophagitis): | 20 mg | Once daily for 4 weeks |
Prevention of recurrence of gastric ulcer or duodenal ulcer during NSAIDs administration | 10 mg | Once a day |
Preparation:
VonizaTM 10: Each box contains 30 tablets in a blister pack.
VonizaTM 20: Each box contains 30 tablets in a blister pack.